These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 12364570)

  • 41. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differential expression of IL-8 and IL-8 receptors in benign, borderline and malignant ovarian epithelial tumours.
    Browne A; Sriraksa R; Guney T; Rama N; Van Noorden S; Curry E; Gabra H; Stronach E; El-Bahrawy M
    Cytokine; 2013 Oct; 64(1):413-21. PubMed ID: 23727325
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CD56 (Neural Cell Adhesion Molecule) Expression in Ovarian Carcinomas: Association With High-Grade and Advanced Stage But Not With Neuroendocrine Differentiation.
    Bösmüller HC; Wagner P; Pham DL; Fischer AK; Greif K; Beschorner C; Sipos B; Fend F; Staebler A
    Int J Gynecol Cancer; 2017 Feb; 27(2):239-245. PubMed ID: 27984374
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunohistochemical patterns for alpha- and beta-catenin, E- and N-cadherin expression in ovarian epithelial tumors.
    Marques FR; Fonsechi-Carvasan GA; De Angelo Andrade LA; Böttcher-Luiz F
    Gynecol Oncol; 2004 Jul; 94(1):16-24. PubMed ID: 15262114
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
    Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
    Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma.
    Zhang C; Wang YE; Zhang P; Liu F; Sung CJ; Steinhoff MM; Quddus MR; Lawrence WD
    Hum Pathol; 2010 Feb; 41(2):255-61. PubMed ID: 19896693
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Monoclonal antibody, Mab 12C3, is a sensitive immunohistochemical marker of early malignant change in epithelial ovarian tumors.
    Yamada K; Ohkawa K; Joh K
    Am J Clin Pathol; 1995 Mar; 103(3):288-94. PubMed ID: 7872250
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression of glucose transporter protein 1 and p63 in serous ovarian tumor.
    Cai Y; Zhai JJ; Feng BB; Duan XZ; He XJ
    J Obstet Gynaecol Res; 2014 Jul; 40(7):1925-30. PubMed ID: 25056472
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Selection of carbohydrate antigens in human epithelial ovarian cancers as targets for immunotherapy: serous and mucinous tumors exhibit distinctive patterns of expression.
    Federici MF; Kudryashov V; Saigo PE; Finstad CL; Lloyd KO
    Int J Cancer; 1999 Apr; 81(2):193-8. PubMed ID: 10188718
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Association of EGFR expression with angiogenesis and chemoresistance in ovarian carcinoma].
    Chen AP; Zhang J; Liu H; Zhao SP; Dai SZ; Sun XL
    Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):48-52. PubMed ID: 19538870
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
    Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
    Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.
    Sieben NL; Macropoulos P; Roemen GM; Kolkman-Uljee SM; Jan Fleuren G; Houmadi R; Diss T; Warren B; Al Adnani M; De Goeij AP; Krausz T; Flanagan AM
    J Pathol; 2004 Mar; 202(3):336-40. PubMed ID: 14991899
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Serum level and expression of vascular epithelial growth factor in ovarian epithelial carcinoma].
    Sun LX; Wu Y; Han HQ; Wang QH
    Ai Zheng; 2003 Jan; 22(1):58-61. PubMed ID: 12561438
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems.
    Wang J; Lin L; Parkash V; Schwartz PE; Lauchlan SC; Zheng W
    Int J Cancer; 2003 Jan; 103(3):328-34. PubMed ID: 12471615
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia.
    Kalir T; Wang BY; Goldfischer M; Haber RS; Reder I; Demopoulos R; Cohen CJ; Burstein DE
    Cancer; 2002 Feb; 94(4):1078-82. PubMed ID: 11920478
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expression of Polypeptide
    Murakami M; Kagami S; Nguyen TT; Koi C; Kurita T; Hachisuga T
    Anticancer Res; 2017 Jul; 37(7):3911-3915. PubMed ID: 28668894
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Overexpression and prognostic value of p53 and HER2/neu proteins in benign ovarian tissue and in ovarian cancer].
    Coronado Martín PJ; Fasero Laiz M; García Santos J; Ramírez Mena M; Vidart Aragón JA
    Med Clin (Barc); 2007 Jan; 128(1):1-6. PubMed ID: 17266884
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Transitional cell-like morphology in ovarian endometrioid carcinoma: morphologic, immunohistochemical, and behavioral features distinguishing it from high-grade serous carcinoma.
    Karnezis AN; Aysal A; Zaloudek CJ; Rabban JT
    Am J Surg Pathol; 2013 Jan; 37(1):24-37. PubMed ID: 23108017
    [TBL] [Abstract][Full Text] [Related]  

  • 59. AGR2 expression in ovarian tumours: a potential biomarker for endometrioid and mucinous differentiation.
    Armes JE; Davies CM; Wallace S; Taheri T; Perrin LC; Autelitano DJ
    Pathology; 2013 Jan; 45(1):49-54. PubMed ID: 23222243
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Stromal p16 expression is significantly increased in malignant ovarian neoplasms.
    Yoon N; Yoon G; Park CK; Kim HS
    Oncotarget; 2016 Oct; 7(40):64665-64673. PubMed ID: 27572321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.